Weekly Paclitaxel and Gemcitabine in Advanced Transitional Cell Carcinoma of the Urothelium: A Phase II Hoosier Oncology Group Study

Abstracts/Posters/Presentations:

• R. Parameswaran, Indiana University, Walther Cancer Institute, M. Fisch, M.D.Anderson Cancer Center, Walther Cancer Institute, C. Sweeney, L. Einhorn, Indiana University, Walther Cancer Institute. A Hoosier Oncology Group Phase II Study of Weekly Paclitaxel and Gemcitabine in Advanced Transitional Cell Carcinoma (TCC) of the Bladder: GU98-2. Accepted as a poster presentation for ASCO annual meeting May 12-15, 2001, San Francisco, CA.
• Jinxing Li MD, Beth Juliar MA MS, Rafat Ansari MD, Edward Fox MD, Michael Fisch MD, Lawrence Einhorn MD, Christopher Sweeney MD. A Phase II Study of Weekly Paclitaxel (P) and Gemcitabine (G) in Advanced Transitional Cell Carcinoma (TCC) of the Urothelium): A Hoosier Oncology Group Study GU98-2. Accepted as a poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL

Manuscripts/Articles:

• Jinxing Li, Beth Juliar, Constantin Yiannoutsos, Rafat Ansari, Edward Fox, Michael J. Fisch, Lawrence H. Einhorn, and Christopher J. Sweeney. Weekly Paclitaxel and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase II Hoosier Oncology Group Study GU98-2. J Clin Oncol 2005;23 1185-1191. See abstract.